Suppressive effect of citalopram on plasma concentrations of thromboxane B₂

References

• Bakish D, Cavazzoni P, Chudzik J, Ravindran A, Hrdina PD. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 1997;41:184–90.
   PubMed Web of Science ®Google Scholar
• Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004;91:119–28.
   PubMed Web of Science ®Google Scholar
• Ellero-Simatos S, Lewis JP, Georgiades A, Yerges-Armstrong LM, Beitelshees AL, Horenstein RB, Dane A, Harms AC, Ramaker R, Vreeken RJ, Perry CG, Zhu H, Sanchez CL, Kuhn C, Ortel TL, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst Pharmacol 2014;3:e125.
   PubMedGoogle Scholar
• Barbui C, Ostuzzi G, Cipriani A. SSRI plus supportive care more effective than supportive care alone for mild to moderate depression. Evid Based Ment Health 2009;12:109.
   PubMedGoogle Scholar
• Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003;163: 59–64.
   PubMed Web of Science ®Google Scholar
• Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006;20:143–51.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009;104:1475–82.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Glassman AH, Malinin AI, Atar D, Sane DC, Oshrine BR, Ferguson JJ, O’Connor CM. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003;5:517–21.
   PubMed Web of Science ®Google Scholar
• Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325:1137–41.
   PubMed Web of Science ®Google Scholar
• Sadilkova L, Paluch Z, Mottlova J, Bednar F, Alusik S. The effect of selected pre-analytical phase variables on plasma thromboxane A(2) measurements in humans. Int J Lab Hematol 2013;35:92–100.
   PubMed Web of Science ®Google Scholar
• Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986;83:5861–5.
   PubMed Web of Science ®Google Scholar
• Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702–8.
   PubMed Web of Science ®Google Scholar
• Kimmel SE, Schelleman H, Berlin JA, Oslin DW, Weinstein RB, Kinman JL, Sauer WH, Lewis JD. The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol 2011;72:514–7.
   PubMed Web of Science ®Google Scholar
• Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894–8.
   PubMed Web of Science ®Google Scholar
• Van Holten TC, Roest M, Riphagen J, Jansen C, Naarding P, Adriaansen HJ, De Groot PG, Remijn JA. Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study. J Thromb Haemost. 2012;10:1177–9.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373: 1849–60.
   PubMed Web of Science ®Google Scholar
• Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010;71:1565–75.
   PubMed Web of Science ®Google Scholar
• Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother 2014;14:539–51.
   PubMed Web of Science ®Google Scholar
• Tseng YL, Chiang ML, Lane HY, Su KP, Lai YC. Selective serotonin reuptake inhibitors reduce P2Y12 receptor- mediated amplification of platelet aggregation. Thromb Res 2013;131:325–32.
   PubMed Web of Science ®Google Scholar
• Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, Gawaz M, Dietz R, Bocksch W. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005;42:99–103.
   PubMed Web of Science ®Google Scholar
• Fitzgerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther 2011;130:213–25.
   PubMed Web of Science ®Google Scholar
• Lopez LR, Guyer KE, Torre IG, Pitts KR, Matsuura E, Ames PR. Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease. World J Diabetes 2014;5: 115–27.
   PubMedGoogle Scholar
• Mosorjakova D, Paluch Z, Alusik S. Aspirin resistance. Bratisl Lek Listy 2007;108:7–13.
   PubMed Web of Science ®Google Scholar
• Park K, Bavry AA. Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events. Cleve Clin J Med 2013;80:318–26.
   PubMed Web of Science ®Google Scholar
• Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, Group PPPC. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26: 3264–72.
   PubMed Web of Science ®Google Scholar
• Hermann M, Waade RB, Molden E. Therapeutic drug monitoring of selective serotonin reuptake inhibitors in elderly patients. Ther Drug Monit 2015 [Epub ahead of print]
   Google Scholar
• Fredericson Overo K, Toft B, Christophersen L, Gylding-Sabroe JP. Kinetics of citalopram in elderly patients. Psychopharmacology (Berl) 1985;86:253–7.
   PubMed Web of Science ®Google Scholar
• Petrovic M, De Paepe P, Van Bortel L. Pharmacotherapy of depression in old age. Acta Clin Belg 2005;60:150–6.
   PubMed Web of Science ®Google Scholar